TY - JOUR
T1 - The approval of a disease-modifying treatment for Alzheimer’s disease: impact and consequences for the nuclear medicine community
AU - Garibotto, Valentina
AU - Albert, Nathalie L.
AU - Barthel, Henryk
AU - van Berckel, Bart
AU - Boellaard, Ronald
AU - Brendel, Matthias
AU - Cecchin, Diego
AU - Ekmekcioglu, Ozgul
AU - van de Giessen, Elsmarieke
AU - Guedj, Eric
AU - Lammerstma, Adriaan A.
AU - Semah, Franck
AU - Traub-Weidinger, Tatjana
AU - van Weehaeghe, Donatienne
AU - EANM Neuroimaging Committee
AU - Morbelli, Silvia
N1 - Funding Information: Matthias Brendel reports grants by the German Research Foundation (projects BR4580/1–1; EXC 2145 SyNergy – ID 390857198), LMU Munich (project 980), and the Alzheimer Forschung Initiative e.V. (project 19063p). Matthias Brendel received speaker honoraria from GE healthcare, Roche, and Life Molecular Imaging, and is an advisor of Life Molecular Imaging. Funding Information: Eric Guedj received financial support from Life Molecular Imaging for an amyloid PET project in 2017; and from GE Healthcare, Curium, and AAA/Novartis on topics unrelated to this article. Funding Information: Valentina Garibotto reports grants from the Swiss National Science Foundation (projects 320030_169876, 320030_185028 and IZSEZ0_188355) the Schmidheiny foundation and the Velux foundation (project 1123). Valentina Garibotto received financial support for research and/or speaker fees through her institution from Siemens Healthineers, GE Healthcare, Life Molecular Imaging, Cerveau Technologies, Roche, Merck.
PY - 2021/9
Y1 - 2021/9
UR - http://www.scopus.com/inward/record.url?scp=85110876653&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s00259-021-05485-y
DO - https://doi.org/10.1007/s00259-021-05485-y
M3 - Editorial
C2 - 34272989
SN - 1619-7070
VL - 48
SP - 3033
EP - 3036
JO - European journal of nuclear medicine and molecular imaging
JF - European journal of nuclear medicine and molecular imaging
IS - 10
ER -